Sitagliptin: a potential drug for the treatment of SARS-CoV-2?

2020 ◽  
Author(s):  
Sanaa Bardaweel
Keyword(s):  
Clinical Trials ◽  
Drug Discovery ◽  
Antimalarial Drug ◽  
Drug Repurposing ◽  
Spike Protein ◽  
Diabetic Patients ◽  
Potential Drug ◽  
Chemokine Production ◽  
Drug Discovery And Development ◽  
Sequence Identity

Recently, an outbreak of fatal coronavirus, SARS-CoV-2, has emerged from China and is rapidly spreading worldwide. As the coronavirus pandemic rages, drug discovery and development become even more challenging. Drug repurposing of the antimalarial drug chloroquine and its hydroxylated form had demonstrated apparent effectiveness in the treatment of COVID-19 associated pneumonia in clinical trials. SARS-CoV-2 spike protein shares 31.9% sequence identity with the spike protein presents in the Middle East Respiratory Syndrome Corona Virus (MERS-CoV), which infects cells through the interaction of its spike protein with the DPP4 receptor found on macrophages. Sitagliptin, a DPP4 inhibitor, that is known for its antidiabetic, immunoregulatory, anti-inflammatory, and beneficial cardiometabolic effects has been shown to reverse macrophage responses in MERS-CoV infection and reduce CXCL10 chemokine production in AIDS patients. We suggest that Sitagliptin may be beneficial alternative for the treatment of COVID-19 disease especially in diabetic patients and patients with preexisting cardiovascular conditions who are already at higher risk of COVID-19 infection.

Sitagliptin: a potential drug for the treatment of SARS-CoV-2?

2020 ◽  
Author(s):  
Sanaa Bardaweel
Keyword(s):  
Clinical Trials ◽  
Drug Discovery ◽  
Antimalarial Drug ◽  
Drug Repurposing ◽  
Spike Protein ◽  
Diabetic Patients ◽  
Potential Drug ◽  
Chemokine Production ◽  
Drug Discovery And Development ◽  
Sequence Identity

Recently, an outbreak of fatal coronavirus, SARS-CoV-2, has emerged from China and is rapidly spreading worldwide. As the coronavirus pandemic rages, drug discovery and development become even more challenging. Drug repurposing of the antimalarial drug chloroquine and its hydroxylated form had demonstrated apparent effectiveness in the treatment of COVID-19 associated pneumonia in clinical trials. SARS-CoV-2 spike protein shares 31.9% sequence identity with the spike protein presents in the Middle East Respiratory Syndrome Corona Virus (MERS-CoV), which infects cells through the interaction of its spike protein with the DPP4 receptor found on macrophages. Sitagliptin, a DPP4 inhibitor, that is known for its antidiabetic, immunoregulatory, anti-inflammatory, and beneficial cardiometabolic effects has been shown to reverse macrophage responses in MERS-CoV infection and reduce CXCL10 chemokine production in AIDS patients. We suggest that Sitagliptin may be beneficial alternative for the treatment of COVID-19 disease especially in diabetic patients and patients with preexisting cardiovascular conditions who are already at higher risk of COVID-19 infection.

scholarly journals Phase I and phase II clinical trials in sarcoma: Implications for drug discovery and development

2019 ◽  
Vol 8 (2) ◽  
pp. 585-592 ◽  
Author(s):  
Daniel Y. Lee ◽  
Arthur P. Staddon ◽  
Jacob E. Shabason ◽  
Ronnie Sebro
Keyword(s):  
Clinical Trials ◽  
Drug Discovery ◽  
Phase I ◽  
Phase Ii ◽  
Drug Discovery And Development ◽  
Phase Ii Clinical Trials

scholarly journals Shotgun Drug Repurposing Biotechnology to Tackle Epidemics and Pandemics

2020 ◽  
Author(s):  
William Mangione ◽  
Zackary Falls ◽  
Thomas Melendy ◽  
Gaurav Chopra ◽  
Ram Samudrala
Keyword(s):  
Clinical Trials ◽  
Drug Discovery ◽  
Computational Analysis ◽  
Drug Repurposing ◽  
The Future ◽  
Respiratory Coronavirus ◽  
Novel Drug

In this manuscript we highlight consensus between the list of drugs currently in clinical trials to treat COVID-19, the worldwide pandemic caused by severe acute respiratory coronavirus 2 (SARS-CoV-2), and the list of predictions made using our shotgun drug discovery, repurposing, and design platform known as CANDO (Computational Analysis of Novel Drug Opportunities). We make the argument that increased funding and development for drug repurposing biotechnology like ours will help combat the inevitable pathogenic outbreaks of the future. <br>

scholarly journals The Stages of Drug Discovery and Development Process

2019 ◽  
Vol 7 (6) ◽  
pp. 62-67 ◽  
Author(s):  
Amol B Deore ◽  
Jayprabha R Dhumane ◽  
Rushikesh Wagh ◽  
Rushikesh Sonawane
Keyword(s):  
Clinical Trials ◽  
Drug Discovery ◽  
Drug Development ◽  
Development Process ◽  
Regulatory Requirements ◽  
Drug Discovery And Development ◽  
Biological Targets ◽  
New Drug ◽  
Initial Discovery ◽  
New Research

Drug discovery is a process which aims at identifying a compound therapeutically useful in curing and treating disease. This process involves the identification of candidates, synthesis, characterization, validation, optimization, screening and assays for therapeutic efficacy. Once a compound has shown its significance in these investigations, it will initiate the process of drug development earlier to clinical trials. New drug development process must continue through several stages in order to make a medicine that is safe, effective, and has approved all regulatory requirements. One overall theme of our article is that the process is sufficiently long, complex, and expensive so that many biological targets must be considered for every new medicine ultimately approved for clinical use and new research tools may be needed to investigate each new target.  From initial discovery to a marketable medicine is a long, challenging task. It takes about 12 - 15 years from discovery to the approved medicine and requires an investment of about US $1 billion. On an average, a million molecules screened but only a single is explored in late stage clinical trials and is finally made obtainable for patients. This article provides a brief outline of the processes of new drug discovery and development.   

scholarly journals Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders

2016 ◽  
Vol 2016 ◽  
pp. 1-12 ◽  
Author(s):  
Hyeong-Min Lee ◽  
Yuna Kim
Keyword(s):  
Drug Discovery ◽  
De Novo ◽  
Drug Repurposing ◽  
Cost Effective ◽  
Neuropsychiatric Disorders ◽  
Mechanisms Of Action ◽  
Drug Discovery And Development ◽  
Cost Effective Method ◽  
Alternative Approach ◽  
Target Effects

Better the drugs you know than the drugs you do not know. Drug repurposing is a promising, fast, and cost effective method that can overcome traditional de novo drug discovery and development challenges of targeting neuropsychiatric and other disorders. Drug discovery and development targeting neuropsychiatric disorders are complicated because of the limitations in understanding pathophysiological phenomena. In addition, traditional de novo drug discovery and development are risky, expensive, and time-consuming processes. One alternative approach, drug repurposing, has emerged taking advantage of off-target effects of the existing drugs. In order to identify new opportunities for the existing drugs, it is essential for us to understand the mechanisms of action of drugs, both biologically and pharmacologically. By doing this, drug repurposing would be a more effective method to develop drugs against neuropsychiatric and other disorders. Here, we review the difficulties in drug discovery and development in neuropsychiatric disorders and the extent and perspectives of drug repurposing.

scholarly journals New approaches in antimalarial drug discovery and development: a review

2012 ◽  
Vol 107 (7) ◽  
pp. 831-845 ◽  
Author(s):  
Anna Caroline C Aguiar ◽  
Eliana MM da Rocha ◽  
Nicolli B de Souza ◽  
Tanos CC França ◽  
Antoniana U Krettli
Keyword(s):  
Drug Discovery ◽  
Antimalarial Drug ◽  
Drug Discovery And Development ◽  
New Approaches
Sign in / Sign up

Export Citation Format

Share Document